In the longer term, risk-reducing surgery, particularly for BRCA1 gene carriers is an appropriate management; in our analysis, the rising hazard for death in BRCA carriers over time was negated by removing from the analysis all patients who developed a second new primary breast or ovarian cancer during the follow-up period. The gene discussed is BRCA1; the disease is ovarian carcinoma.